Primary Ewing Sarcoma of the Kidney in a 54-Year-Old Male: A Rare Case Report

Yusuf Ilhan, Ceren Suntur, Havva Serap Toru, Onur Ertunc, Ali Murat Tatli, Hasan Senol Coskun, Sema Sezgin Goksu

Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Türkiye
Department of Internal Medicine, Akdeniz University Faculty of Medicine, Antalya, Türkiye
Department of Pathology, Akdeniz University Faculty of Medicine, Antalya, Türkiye
Department of Pathology, Suleyman Demirel University Faculty of Medicine, Isparta, Türkiye

Abstract

Ewing sarcomas/Primitive neuroectodermal tumors are aggressive tumors, typically seen in children and young adults. These tumors are of neuroectodermal origin and, also known as Ewing sarcoma family tumors. They are most commonly seen in the bones and soft tissues. Primary Ewing sarcoma of the kidney is rarely seen. It has nonspecific symptoms and imaging findings. Therefore, it is mostly diagnosed postoperatively. Its diagnosis is based on histological morphology, immunohistochemistry and, molecular genetic tests. A multi-modality treatment approach is very important. Here, we presented a male patient with primary Ewing sarcoma of the kidney, relatively in older age. A 54-year-old male patient admitted to the hospital with right flank pain and hematuria. He was operated successfully and than received adjuvant vincristine, doxorubicin, cyclophosphamide, and ifosfamide, etoposide chemotherapy regimens. No treatment-related toxicity was observed and the patient is still in remission. Despite using surgery and adjuvant chemotherapy in treatment, because of its rarity there was no randomized trial about kidney Ewing sarcomas. These rare tumors still need robust therapeutic treatment regimens.

Keywords: Ewing sarcoma, kidney sarcomas, kidney tumor

Case Report

A 54-year-old male patient admitted to the hospital with right flank pain and hematuria. He had no other significant medical history. He had 30-pack-year smoking history and moderate alcohol consumption. Because of these symptoms, urinary ultrasonography was performed and nearly 7 cm solid mass was found in the right kidney. Computed tomography (CT) was performed upon the detection of a mass in the right kidney. A heterogeneously enhanced hyperdense cystic mass lesion, approximately 74*63 mm in size located in the upper pole of the right kidney was observed and renal cell carcinoma was considered in the differential diagnosis (Figs. 1, 2). The patient underwent a right radical nephrectomy. In the intra-operative observation, there was a mass about 7 cm extending from the middle pole of the right kidney towards the upper pole and anterior of the kidney. There was no invasion to the renal artery and vein. On pathological gross examination, there was a large tumour (6,9*6,1*6 cm) in the right kidney. The mass has infiltrated the renal parenchyma. Nuclear polymorphism, spindle cells, and rosette formation were observed in microscopic examination. Immunohistochemical examination revealed vimentin, cd99, fli-1 positive staining; synaptophysin, sma, myogenin, ck18 negative staining. Widespread CD99 and fli-1 positivity were observed in the case. In addition to morphologic and immunohistochemistry findings, for differential diagnosis of these tumors, EWSR1 gene rearrangement was performed using fluorescent in situ hybridization (FISH) technique. In FISH analyze, 30% of tumor cells were positive for EWSR1 rearrangement. (Fig. 3). Because of widespread CD99 and FLI-1 positivity, and EWSR1 gene rearrangement positivity, primary Ewing sarcoma of kidney was considered after the pathologic evaluation. Positron emission tomography/computed tomography was taken for postoperative staging and distant metastasis was not observed. The patient received adjuvant vincristine, doxorubicin, cyclophosphamide (VAC), and ifosfamide, etoposide (IE) chemotherapy regimens, alternately every 3 weeks. No treatment-related toxicity was observed and the patient is still in remission.

Discussion

Primary Ewing sarcoma of the kidney is a rare kidney tumor, accounting for less than 1% of all renal tumors. It mostly affects young adults, most commonly in the 2nd and 3rd decade. There is also a slight male dominance. Our case was 54 years old and, moderate older comparing with usual Ewing sarcomas.[1–3] Clinical signs and symptoms are nonspecific such as flank pain, hematuria, and palpable mass. Furthermore, no specific finding for ES/PNET has been identified in ultrasonography and computed tomography or magnetic resonance imaging. The imaging features of most renal sarcomas are indistinguishable from renal carcinoma.[4] In our case, similar to the cases in the literature, with CT imaging, renal cell carcinoma was considered, but after the operation, the pathology report was given as Ewing sarcoma. So, the diagnosis of ESK is mostly made post-operatively.

Histologically, ESK consists of small round cells. The differential diagnosis includes wilms tumor, neuroblastoma, synovial sarcoma, renal cell carcinoma, malignant lympho-
ma, solid variant of alveolar rhabdomyosarcoma, small cell neuroendocrine carcinoma, desmoplastic small round cell tumor, and small cell carcinoma. These small round cell tumors have similar morphological features but different prognoses. Therefore, the diagnosis should be supported by immunohistochemistry and molecular analysis in order to distinguish. CD99 and FLI-1 positivity are common in ES/PNET including ESK. In molecular analysis performed by FISH technique, ES/PNET is characterized by translocation between EWS (22q12) and FLI-1 (11q24) genes.

ES/PNET is an aggressive disease, grows rapidly and may metastasize early to the lung, liver, bone, and lymph nodes. An increase in survival was observed with aggressive adjuvant therapy in localized Ewing sarcomas. Currently, there is still no standard treatment for ESK. Mostly, they are treated with multi-agent chemotherapy knowing from classic bone Ewing sarcoma’s trials regimens after radical nephrectomy. Symptoms of our patient were developed in a short time, and when he was admitted to the hospital a gross mass, approximately 7 cm was detected. We also preferred to treat patient with VAC-IE alternating adjuvant chemotherapy regimens after radical nephrectomy. However, patients with metastatic disease at the time of the first diagnosis had a poor prognosis. In chemotherapy, vincristine, ifosfamide, adriamycin, etoposide, cyclophosphamide, and actinomycin-D are widely used in both localize and metastatic diseases. If there is venous thrombosis associated with pulmonary metastasis, cavotomy may be added to the surgical intervention. If the surgical margin is positive or there is a localized lymph node involvement, radiotherapy should be added to the treatment as salvage therapy. However, there are conflicting opinions regarding the use of radiotherapy as first-line treatment. There are claims that anti-tumor agents such as apatinib, an angio-

Figure 3. (a, b) Small round cell tumor in Kidney (Light microscopy H&E stain a: x40 b: x400). (c) The immunohistochemical FLI-1 nuclear expression in tumor cells (Light Microscopy IHC FLI 1 stain, x400). (d) The EWSR1 (22q12) dual-color, break-apart rearrangement (Immunofluorescent microscopy, FISH analysis, x200).
genic drug, may be one of the treatment options for ESK, but more studies are needed to confirm their benefits on the disease.

**Conclusion**

Renal ES/PNET is a rare, aggressive malignancy. It is predominantly seen in young adults. Patients mostly present with nonspecific symptoms such as flank pain, hematuria, and palpable mass. There is no specific finding in imaging studies. However, imaging is required to evaluate the mass preoperatively and to detect metastases. The diagnosis of ES/PNET is based on histomorphology, immunohistochemical staining, and molecular genetic testing. Multimodal therapy including surgery, chemotherapy, and radiotherapy is indicated. Currently, the most common treatment is surgery and adjuvant chemotherapy for localize Ewing sarcoma of the kidney. However, this malignancy still needs stronger therapeutic regimens.

**Disclosures**

**Informed Consent:** Written informed consent was obtained from the patient for the publication of the case report and the accompanying images.

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** None declared.


**References**